<DOC>
	<DOCNO>NCT01697319</DOCNO>
	<brief_summary>The primary objective study evaluate effect 2.0 mg/kg/week BMN 110 patient population limit ambulation , period 144 week .</brief_summary>
	<brief_title>Efficacy Safety Study BMN 110 Morquio A Syndrome Patients Who Have Limited Ambulation</brief_title>
	<detailed_description>Effect define follow key domain : - Upper extremity function dexterity - Mobility</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis IV</mesh_term>
	<criteria>Is willing able provide write , sign inform consent ( legally authorize representative ) nature study explain prior performance researchrelated procedure . Patients meet country local age requirement informed consent must willing able provide write assent nature study explain prior performance researchrelated procedure . Has document clinical diagnosis MPS IVA base clinical sign symptom MPS IVA document reduce fibroblast leukocyte GALNS enzyme activity genetic test confirm diagnosis MPS IVA . Is â‰¥ 5 year age . If sexually active , willing use acceptable method contraception participate study . Females childbearing potential must negative pregnancy test Screening Visit willing additional pregnancy test study . Is willing able perform study procedure physically possible . Is able walk far specify distance assess 6MWT . Has previous hematopoietic stem cell transplant ( HSCT ) . Has receive previous treatment BMN 110 . Has know hypersensitivity component BMN 110 . Has major surgery within 3 month prior study entry planning major surgery first 24 week study . Has use investigational product investigational medical device within 30 day prior Screening Visit require investigational agent prior completion schedule study assessment . Is pregnant breastfeed Screening Visit plan become pregnant ( self partner ) time study . Has concurrent disease condition , include limited symptomatic cervical spine instability severe cardiac disease complete paralysis due spinal cord injury ( define inability move arm leg ) , would interfere study participation safety determine Investigator . Has condition , view Investigator , place patient high risk poor treatment compliance complete study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Mucopolysaccharidosis IVA Type A</keyword>
	<keyword>MPS IVA Type A</keyword>
	<keyword>Mucopolysaccharidosis IVA</keyword>
	<keyword>MPS IVA</keyword>
	<keyword>Morquio A Syndrome</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
	<keyword>LSD</keyword>
	<keyword>N-acetylgalactosamine-6-sulfatase</keyword>
	<keyword>N-acetylgalactosamine-6-sulfate</keyword>
	<keyword>sulfatase</keyword>
	<keyword>galactose-6-sulfatase</keyword>
	<keyword>GALNS</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>ERT</keyword>
	<keyword>MOR-006</keyword>
	<keyword>CPET</keyword>
	<keyword>Limited ambulation</keyword>
	<keyword>Grip/ Pinch</keyword>
</DOC>